UD Info DB Series SSD Drives Achieve FIPS 140-3 Validation

Milestone completes a three-year security certification roadmap and advances secure storage for regulated industries and mission-critical applications

NEW TAIPEI CITY, Sept. 20, 2026 /PRNewswire/ -- UD info today announced that the cryptographic module integrated into its DB Series SSD Drives has achieved FIPS 140-3 validation through the National Institute of Standards and Technology (NIST) Cryptographic Module Validation Program (CMVP). NIST CMVP Certificate No. 5479, issued August 12, 2026, confirms validation at Overall Level 2.

The milestone provides independent assurance that the DB Series cryptographic module meets recognized security requirements. It also helps customers address security, compliance, and procurement requirements across government, critical infrastructure, and other mission-critical applications.

"FIPS 140-3 validation reflects our commitment to security backed by independent validation," said Gibson Chen, General Manager of UD info. "It strengthens our ability to help customers meet compliance requirements while delivering the performance, reliability, and long-term availability required for mission-critical applications."

FIPS 140-3 is the current U.S. federal security standard for cryptographic modules. This achievement completes UD info's three-year security roadmap, following FIPS 140-2 validation for the DA Series in 2024 and Common Criteria certification in 2025. Together, these milestones demonstrate UD info's investment in independently validated security and strengthen its position as a trusted secure-storage partner for regulated and mission-critical applications worldwide.

Designed for diverse system architectures and deployment environments, the DB Series is available in five certified configurations, combining hardware-based AES-XTS-256 encryption with NVMe PCIe performance and support for the TCG Opal Security Subsystem Class (SSC) protocol.

Full product specifications and datasheets are available for download at https://www.udinfo-tech.com/products/ruggedapplications.

UD info will continue to invest in certification, encryption, and firmware development to expand its secure storage portfolio. By combining validated security with strong firmware expertise and long-term supply commitments, UD info helps customers reduce integration risk and build dependable platforms for security-sensitive applications.

About UD info

UD info is a Taiwan-based manufacturer of industrial-grade storage solutions, including SSDs, SD and microSD cards, eMMC, USB flash drives, and DRAM modules. Backed by strong firmware engineering capabilities and long-term supply commitments, UD info serves customers worldwide across industrial automation, transportation, medical, energy, aerospace, rugged computing, and embedded systems. To learn more, visit www.udinfo.com.tw.

Media Contact:

[email protected] 

SOURCE UD info

Share this article

MetaOptics Secures up to US$10 Million Investment Facility from White Lion Capital, Its First U.S. Institutional Investor, to Onshore Metalens Technology into the U.S.

SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group"), a leading-edge semiconductor optics company pioneering metalens technology, today announced that it has secured an investment facility of up to US$10 million from White Lion Capital LLC ("White Lion"), pursuant to a warrant deed entered into with White Lion, under which the Company may, upon exercise of the warrants by the holder at its discretion, raise up to US$10 million through the issuance of up to 40,000,000 new ordinary shares of the Company. White Lion, based in Los Angeles, California, is the first institutional investor in the United States ("U.S.") to participate in and invest in MetaOptics' growth story, a strong validation of MetaOptics' technology, solutions and commercialisation roadmap.

The investment comes one year after MetaOptics' listing on the Catalist board of the Singapore Exchange. It follows a period of strong commercial momentum, with design and evaluation requests from world-class customers and sampling units shipped. White Lion's participation extends the Company's investor base beyond Asia into the U.S., its largest end market.

The proceeds of up to US$10 million, upon exercise of the warrants, will accelerate MetaOptics' expansion in the U.S.. White Lion's investment will not just support ongoing projects with U.S. customers across consumer devices, co-packaged optics ("CPO") and optical interconnects, but more importantly, fund the establishment of the Group's maiden front-end semiconductor fabrication line with 12-inch DUV immersion photolithography equipment in the U.S., for the mass production of metalenses and module. The establishment of the Group's maiden front-end semiconductor fabrication line will not only onshore key metalens design, manufacturing and testing into the U.S., bringing such capabilities closer to U.S. customers, but also provide a shorter and clearer roadmap to securing purchase orders for the mass production of metalenses and modules.

The U.S. is a key market for metalens adoption, driven by consumer electronics, AR/VR wearables, automotive sensing and the multi-billion dollar CPO industry serving AI data centres. MetaOptics is currently working with several U.S. foundries to integrate its metalenses into their CPO designs. The smallest CPO metalens designed by MetaOptics measures 0.1 mm. The design can be scaled to a 12-inch semiconductor photolithography process on glass substrates, which is key to mass production.

"Securing our first U.S. institutional investor is an important step for MetaOptics," said Mr Thng Chong Kim, Executive Chairman of MetaOptics. "Many of our most important customers are in the U.S., from consumer device brands to the companies building CPO and optical interconnects for AI data centres. This funding allows us to move faster on their projects and to onshore key metalens technology into the U.S.."

"MetaOptics is one of the few companies in the world that can design, mass-produce and test glass-based metalenses at scale," said Gabriel Gumbiner, Senior Associate of White Lion. "We are particularly pleased that our first investment in an SGX-listed company is with an organization of MetaOptics' caliber. The company has a strong management team with a clear vision for its growth, and we are proud to support MetaOptics as it expands its presence in the U.S. market."

This press release is to be read in conjunction with MetaOptics' announcement on White Lion's investment facility of up to US$10 million, pursuant to a warrant deed entered into with White Lion, released via SGXNet on 21 September 2026. The Company will make further announcement(s) as and when appropriate.

About MetaOptics Ltd

MetaOptics Ltd (Catalist: 9MT) is a vertically integrated designer and manufacturer of metalens-based optical components and products, headquartered in Singapore. Founded in 2021, the Company uses semiconductor processes to pioneer glass-based colour metalenses and produce them at scale on both 4-inch and 12-inch platforms. Its portfolio spans metalenses, metalens camera modules, metalens manufacturing equipment and metalens IoT products, which customers integrate into applications including smartphones, contactless 3D biometrics, AR/VR devices, pico projectors, LiDAR and automotive sensing. MetaOptics aims to deliver high-performance optics with the reliability and scalability demanded by today's most innovative technology brands. Find out more at www.metaoptics.sg.

About White Lion Capital

White Lion Capital LLC is a US-based private investment firm headquartered in Los Angeles, California. The firm provides growth capital to public companies seeking to become leaders in emerging technology sectors.

Forward-Looking Statements

This press release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the Company's growth strategies, its future business development, results of operations and financial condition, its research and development efforts, its ability to attract and retain customers, and its ability to establish and maintain relationships with suppliers and business partners; and assumptions underlying or related to any of the foregoing. All information provided in this press release is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Singapore (Headquarters)

MetaOptics Technologies Pte Ltd, 81 Ayer Rajah Crescent, #01-45, Singapore 139967

United States

MetaOptics Inc. (USA), 1 Ferry Building, Suite 201, San Francisco, CA 94111

SOURCE MetaOptics Ltd

Share this article

- Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry's most extensive therapeutic pipeline.

- ITM is the world's leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production.

- ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals.

- ITM's commercial-scale and profitable isotope production business significantly contributes to cash generation while deepening Telix's supply chain for isotopes required for its therapeutics pipeline.

- ITM's complementary pipeline includes ITM-11 (177Lu-edotreotide), a novel therapeutic candidate for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which has successfully completed Phase 3 development, potentially accelerating Telix's entry into a validated commercial market for targeted radionuclide therapy (TRT).

- Upfront consideration of US$1.65 billion on a cash-free/debt-free basis. After adjustments, ITM Shareholders are expected to be paid approximately US$1.25 billion in Telix Shares at US$11.84[1] per share, released as Nasdaq ADRs after the respective escrow periods.

- Additional contingent consideration of up to US$700 million upon achievement of future regulatory approvals and commercial sales milestones for ITM-11.

- The transaction is subject to Telix Shareholder approval and other customary closing conditions.

MELBOURNE, Australia, INDIANAPOLIS and MUNICH, Sept. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE ("ITM"), a global leader in radioisotope production and radiopharmaceutical development.

The merger will further strengthen Telix's leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organization will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry's most extensive therapeutic radiopharmaceutical pipeline.

Founded in 2004, ITM is a private company with a leading commercial scale radioisotope manufacturing and global distribution network spanning over 65 countries. ITM is a key supplier of 177Lu and – with a compound annual growth rate (CAGR) of 40% from 2021 to 2025 – delivered annual revenue of US$273 million in 2025[2]. This commercial momentum is underpinned by increasing global demand for TRT and radioisotopes for commercially approved products and assets under clinical development. The global nuclear medicine market is forecast to reach US$41 billion by 2034[3].

ITM's late-stage novel pipeline is complementary to Telix and includes ITM-11 (177Lu-edotreotide), a differentiated somatostatin receptor (SSTR)-targeted treatment for GEP-NETs. ITM-11 has completed a successful Phase 3 trial (COMPETE, NCT03049189)[4] and fully enrolled a second indication expansion Phase 3 study (COMPOSE, NCT04919226) with an interim analysis expected in H1 2027. If approved, ITM-11 has the potential to accelerate Telix's entry into the commercial therapeutic market and expand its presence in neuroendocrine tumors, a commercially validated and clinically significant market for TRT.

The combined organization is expected to generate unaudited pro forma 2026 revenue and income exceeding US$1.3 billion[5], based on management estimates. ITM's radioisotope manufacturing business is profitable and generates cash flow. Continued growth from manufacturing, cost savings and further targeted synergies and pipeline optimization are expected to support a positive EBITDA[6] contribution in 2027[7] and onward. If approved by health regulators, the launch of ITM-11 is expected to drive further upside, with the potential to generate additional high-margin therapeutic revenue in the near term.

Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said, "This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector. Importantly, this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security, while bringing together the mission-critical capabilities needed to deliver radiopharmaceutical treatments to patients around the world."

ITM Chief Executive Officer, Dr. Andrew Cavey, added, "Joining two radiopharmaceutical pioneers creates a company with unmatched breadth and depth across the value chain, supported by deep expertise and talent. Our management teams have a track record of working together and a nuanced understanding of our respective commercial strengths and customer relationships. Together, we believe Telix and ITM will be uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals to the benefit of both shareholders and patients."

Deal Terms

Under the terms of the agreement and subject to Shareholder approval, Telix will acquire 100% of the shares in ITM for US$1.65 billion upfront on a cash-free/debt-free basis expected as follows:

- US$1.25 billion will be paid to the sellers in the form of 105.8 million Telix shares (priced at the 30-day trailing VWAP as of signing of US$11.84[1]) and released to the sellers as Nasdaq-listed ADRs at the end of their respective escrow periods;

- US$302 million of net debt will be assumed by Telix at closing; and

- US$96 million of management equity rollover and transaction expenses payable by the sellers[8]; and in each case subject to closing adjustments.

Additional contingent consideration of up to US$700 million will become payable upon the achievement of specified regulatory approvals and sales milestones for ITM-11 as set out below:

- Up to US$250 million upon U.S. Food and Drug Administration (FDA) approval of ITM-11 across three different indications:

- US$100 million upon FDA approval for expected first indication in G1-G2 GEP-NETs no later than December 31, 2027;

- US$100 million upon FDA approval for G2-G3 GEP-NETs indication no later than December 31, 2030; and

- US$50 million upon FDA approval for Lung NETs indication no later than December 31, 2031; and

- Up to US$450 million based on ITM-11 net global sales in FY 2030 in excess of US$150 million.

All milestone consideration will be payable in cash or Shares[9] at Telix's election[10]. Consideration paid to ITM Shareholders at closing is subject to financial adjustments at closing, indemnity holdbacks, and escrow (lockup) restrictions on the Shares issued at closing of up to 15 months which may be waived in limited part to allow the sellers to pay their tax and transaction expense liabilities.

Upon completion of the transaction, Telix Shareholders will own approximately 76.3% and ITM Shareholders will own approximately 23.7% of Telix shares on issue. The transaction has been approved by Telix's Board of Directors and, as of signing, Shareholders holding over 90%[11] of ITM's Shares. The transaction is expected to close by the end of FY 2026 subject to Telix Shareholder approval as required under the ASX Listing Rules, regulatory approvals, and other customary closing conditions.

Refer to the Investor Presentation lodged today with the ASX for further information on the transaction.

A Notice of Meeting will be sent to Telix Shareholders for an extraordinary general meeting expected to be held in November 2026.

Advisors

Morgan Stanley Australia Limited acted as exclusive financial advisor to Telix. Sidley Austin LLP and Herbert Smith Freehills Kramer LLP acted as legal counsel to Telix. Centerview Partners acted as exclusive financial advisor to ITM. Latham & Watkins LLP acted as legal counsel to ITM.

About ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company aims to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all it does, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging two decades of pioneering radiopharma expertise, its respected industry position and its established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life.

ITM is headquartered in Munich, Germany with two GMP manufacturing sites and a global distribution network spanning 65 countries. Through its agreement with Isogen, ITM has 15-year exclusive access to Bruce Power's nuclear reactors in Canada for the irradiation services required to manufacture 177Lu. For further information, visit: www.itm-radiopharma.

SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- 21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, in children with achondroplasia (ACH). In the first and lowest dose cohort of 0.064mg/kg QD, children aged 6 years and older with ACH who received lavengratinib for 27 weeks achieved a mean increase of +2.4 cm/year in annualized height velocity (AHV) from baseline, with a 100% responder rate*. Lavengratinib was well-tolerated with no observed FGFR1 or FGFR2-associated adverse events (AEs).

ABSK061-202 is a Phase II, multicenter, open-label, dose-escalation study designed to evaluate the safety and efficacy of lavengratinib (once daily, orally administered) in children aged 3 to 12 years with ACH. All participants will receive lavengratinib for a planned treatment duration of 78 weeks. To date, all seven participants aged 6 to 12 years in cohort 1 have completed six months of treatment and achieved encouraging preliminary results:

- Preliminary data demonstrate positive signals for growth promotion. At Week 27, the seven participants in the first and lowest dose cohort (0.064 mg/kg, once daily) achieved a mean improvement of +2.4 cm/year in AHV from baseline, with a responder rate* of 100%. Participants enrolled in higher dose cohorts are currently ongoing treatment.

- Overall safety and tolerability were favorable. To date, no serious adverse events (SAEs) or treatment discontinuations due to AEs have been reported. No specific safety risks associated with FGFR pathway inhibition have been observed to date, including FGFR1 or FGFR2-associated AEs such as hyperphosphatemia and corneal toxicity.

- Lavengratinib leverages Abbisko's unique oral mini-tablet formulation. Abbisko's unique mini-tablet formulation, with each tablet being less than 3mm in diameter as compared to conventional tablets ~8-10mm in diameter, allows for easy administration with children. Such mini-tablets can be conveniently administered with food and drink.

The ABSK061-202 study has successfully completed the preliminary safety evaluation of the first three dose cohorts, with no safety concerns identified to date. Six-month efficacy and safety results are expected by the end of 2026, providing further evidence to support the evaluation of the clinical potential of lavengratinib in children with ACH.

*Responder is defined as a participant achieving an ≥25% improvement in AHV from baseline.

About Lavengratinib (ABSK061)

Lavengratinib is a novel, orally bioavailable, highly potent and selective small molecule inhibitor of FGFR2 and FGFR3 independently discovered and wholly-owned by Abbisko Therapeutics. It is the first FGFR2/3 inhibitor to enter clinical trials globally. First-generation pan-FGFR inhibitors demonstrated clinical efficacy in multiple tumors carrying FGFR2/3 variants and have steadily gained regulatory approval globally. However, the therapeutic window of pan-FGFRs and their clinical efficacy have been limited by side effects associated with FGFR1 inhibition. By reducing FGFR1 activity while maintaining potency against FGFR2 and FGFR3, lavengratinib is expected to achieve a wider therapeutic window with improved clinical efficacy as a new-generation of FGFR inhibitors. lavengratinib for the treatment of achondroplasia has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA), and its Phase II clinical trial is currently ongoing.

SOURCE Abbisko

Share this article

LG Display launches 24.5-inch 720Hz Gaming OLED Panel

SEOUL, South Korea, Sept. 20, 2026 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today its launch of a 24.5-inch 720Hz Gaming OLED panel, leading the esports monitor market paradigm.

The company's 24.5-inch 720Hz Gaming OLED panel is the first-ever OLED panel tailored specifically for esports.

Standard monitors used for esports are primarily in the 24-inch class, enabling players to view the entire screen at a glance.

By initiating mass production of its 24.5-inch 720Hz Gaming OLED panel, LG Display aims to pioneer the mainstreaming of OLED technology across the esports monitor market.

The panel realizes the world's highest refresh rate (720Hz) among gaming OLED displays as well as the fastest response time (0.02ms). Refresh rate refers to the number of times per second a screen updates, so 720Hz means the screen refreshes 720 times per second. The core technology lies in a stable driving algorithm, going beyond simply displaying scenes.

LG Display developed a proprietary algorithm to stably drive the 720Hz refresh rate even at FHD (1920x1080) resolution, applying an integrated solution spanning from panel design to the driving system.

Through this ultra-high refresh rate and lightning-fast response time, motion blur and ghosting are dramatically reduced, delivering an overwhelming user experience in fast-paced genres such as first-person shooter (FPS) and racing games. For example, the panel provides exceptional clarity and smoothness, clearly capturing the flash of a gun muzzle or the speed of a vehicle hurtling around a track.

Furthermore, unlike LCDs that require a backlight, each pixel emits light independently to achieve highly vivid picture quality, maximizing player immersion.

The panel has first been applied to global monitor manufacturer ASUS's new gaming monitor, the ROG Swift OLED PG259QWS Ace. This monitor has been selected as the official esports monitor for PGL CS2 Major Singapore 2026, one of the biggest tournaments in the Counter-Strike 2 calendar.

With the launch of its 24.5-inch 720Hz Gaming OLED panel, LG Display plans to accelerate its strategy to target the esports market. The company intends to lead the gaming display market based on its full lineup ranging from the 20-inch to the 40-inch class, with some products featuring its proprietary Dynamic Frequency & Resolution (DFR) technology. To further widen the gap with followers, LG Display is accelerating AI transformation (AX) across all areas of gaming display development.

"As a technology-driven company, we will lead the transition to OLED in the gaming monitor market and lead the mainstreaming of OLED in the global market," said Hyeon-woo Lee, Head of the Large Display Business Unit at LG Display.

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world's leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 53,049 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:

Joo Yeon Jennifer Ha, Team Leader, Communication Team

Email: [email protected] 

SOURCE LG Display

Share this article

Convera and JustLogin Partner to Enable Cross-Border Payroll and Payments Across Singapore and Southeast Asia

- Partnership brings regulated, multi-currency payments into everyday HR workflows, supporting companies as they scale teams, payroll and operations

SEATTLE, Wash. and LONDON, Sept. 20, 2026 /PRNewswire/ -- Convera, a global leader in commercial payments, and JustLogin, an AI-Powered Singapore-based human resource cloud platform operating for the last 26 years, today announced a partnership that brings embedded cross-border payroll and business payment capabilities directly into the HR workflows.

The partnership is designed to support companies operating and expanding across Singapore and Southeast Asia where hiring, managing and paying teams across multiple countries and currencies is now a prerequisite for regional growth. Through the integration, JustLogin customers will be able to initiate payroll and employee-related payments in up to 16 currencies from within the JustLogin platform, while Convera manages the underlying cross-border payment execution.

The result: faster salary disbursement, improved visibility, and reduced operational complexity for companies managing distributed workforces across the region.

"Growing companies should not have to choose between regional expansion and payroll confidence. By embedding Convera's global payments capabilities directly into JustLogin's HR platform, we're making it easier for businesses to hire, pay and scale across Southeast Asia with greater speed, visibility and control", said Patrick Gauthier, Group CEO of Convera, "This partnership reflects a broader shift we're seeing in the market, as payments become more deeply embedded into the platforms businesses already use to run their operations."

As businesses across Southeast Asia build more distributed and regional workforces, payroll is becoming more than an administrative function. It is increasingly connected to employee experience, operational resilience, and the ability to expand into new markets with confidence. The Convera and JustLogin partnership brings together HR technology and embedded financial services to help businesses manage this complexity through a single, integrated experience.

Designed for regulated environments, the integration allows payment activity to be initiated within JustLogin, with essential transaction data shared securely with Convera at the point of payment. Payment status and confirmations are then returned to the JustLogin dashboard, giving HR and finance teams visibility without disrupting existing workflows. As the licensed payment processor, Convera conducts customer onboarding and KYC checks and operates under the oversight of more than 60 regulators worldwide

Cross-border payroll and B2B payouts represent a significant and growing segment of Southeast Asia's payments landscape, with the regional B2B payments market estimated at approximately USD 44.5 billion in 2024 and projected to exceed USD 105 billion by 2033. As Singapore-based and multinational businesses expand across the region, navigating multiple currencies, payment rails, and regulatory regimes has become an increasing challenge. Embedding regulated cross-border payments into HR platforms helps remove a major barrier into regional expansion.

"As our customers expand across markets, payroll and payments have become a critical part of both employee experience and corporate reputation," said KC Kwa, CEO, JustLogin. "In an environment marked by regulatory change and currency volatility, this partnership provides the governance, resilience, and confidence our customers need to keep payroll compliant, accurate, and seamless – without compromising trust."

The solution also leverages select government-backed fast payment rails to accelerate salary disbursement across the region, including Singapore's FAST, Malaysia's DuitNow, and InstaPay in the Philippines.

The Convera and JustLogin integration is available to JustLogin customers in Singapore and across supported Southeast Asian markets, helping businesses build, manage and pay regional workforces through a more connected HR and payments experience.

Additional Resources

- Learn how Convera makes smart money moves

- Follow Convera on LinkedIn and Instagram

- Read Convera's blog for the latest market insights and FX news

- Sign up to attend a Convera Live roadshows

- Look out for Convera at other upcoming industry shows

About Convera

Convera is a global leader in commercial payments. With an unrivaled regulatory footprint and a financial network spanning more than 140 currencies and 200 countries and territories, Convera is reimaging the future of business payments. We combine tech-led payment solutions with deep expertise in foreign exchange, risk management, and compliance. From small businesses to CFOs and treasurers, we're helping our customers grow with confidence. Convera makes business payments simple, smart, and secure.

SOURCE Convera

Share this article

Velocys expands Fischer-Tropsch reactor roadmap with AlphaCore 800 for larger-scale SAF and e-fuels projects

Larger-capacity microchannel reactor is designed to reduce reactor count, simplify FT configuration and lower FT unit cost

HOUSTON and OXFORD, England, Sept. 21, 2026 /PRNewswire/ -- Velocys, a Fischer-Tropsch technology licensor for sustainable fuels, today announced the release of the new AlphaCore™ 800 reactor, its highest-capacity microchannel Fischer-Tropsch (FT) reactor to date. It is designed to produce up to 800 barrels per day, or 30,000 tonnes per year (30 kt/a) of FT fluids from a single reactor.

AlphaCore 800 doubles the capacity of AlphaCore 400 and extends Velocys' throughput-based AlphaCore reactor family from approximately 50 to 800 barrels per day per reactor (from 2 to 30 kt/a per reactor). AlphaCore 800 is designed particularly for larger sustainable aviation fuel (SAF) and e-fuels projects, including SAF plants targeting approximately 100,000 tonnes per year and above.

Benefits from expanding reactor size while preserving the underlying chemistry and design are clear: more FT capacity per reactor, enabling fewer reactors as project scale increases without sacrificing performance or reliability. Reducing reactor count can simplify the FT island, reduce associated equipment requirements and lower FT unit cost.

For example, an FT plant requiring approximately 1,600 barrels per day (60 kt/a) of FT liquids could be configured with two AlphaCore 800 reactors. This reduces total reactor count by 75% compared to an FT unit utilizing eight AlphaCore 200 reactors while maintaining the same FT liquids capacity.

"Customers are asking us to bring our microchannel FT technology into larger projects with simpler configurations," said Matthew Viergutz, CEO of Velocys. "AlphaCore 800 is a direct response. As SAF projects move toward 100,000 tonnes per year and beyond, we are increasing capacity per reactor so developers can configure larger FT plants with fewer units while building on the technology platform and operating experience of Velocys."

AlphaCore 800 joins AlphaCore 50, 200 and 400 in the Velocys reactor portfolio, giving project developers a throughput-based product range built with the same core technology that can be applied across multiple project scales and syngas pathways.

The Velocys roadmap reflects growing market demand for scalable SAF and e-fuels production, where developers look to reduce plant complexity, improve repeatability and strengthen the commercial case for larger FT-based projects.

About Velocys

Velocys is a Fischer-Tropsch technology licensor for sustainable fuels. Its microFTL™ platform combines AlphaCore™ microchannel reactors, SQRCAT™ catalyst and process know-how to convert synthesis gas into liquid hydrocarbons for SAF, renewable diesel and other synthetic fuels.

Learn more at Velocys.com.

Share this article

Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022

SHANGHAI and HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the first patient has been dosed in China in the pivotal Phase III CLINCH-3 study of ATG-022. ATG-022 is a CLDN18.2 antibody-drug conjugate (ADC) being evaluated for the treatment of CLDN18.2+ advanced gastric or gastroesophageal junction adenocarcinoma.

ATG-022 was previously granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). This designation has facilitated efficient regulatory communications and supported the rapid advancement of the CLINCH-3 study. Initiated in China with the first patient dosed and planned for expansion into a multi-regional clinical trial (MRCT), the CLINCH-3 study is intended to generate robust clinical evidence to support a future marketing approval application for ATG-022 as monotherapy for CLDN18.2+ advanced gastric or gastroesophageal junction adenocarcinoma.

The CLINCH-3 study is led by Prof. Lin Shen from Peking University Cancer Hospital as the principal investigator. This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of ATG-022 versus treatment of investigator's choice in patients with CLDN18.2+ advanced gastric or gastroesophageal junction adenocarcinoma. The initiation of this pivotal study is supported by encouraging results from the Phase I/II CLINCH studies, which showed that ATG-022, as monotherapy, demonstrated a differentiated robust efficacy and well tolerated safety profile in patients with advanced gastric or gastroesophageal junction adenocarcinoma. As of June 26, 2026, among patients with moderate to high CLDN18.2 expression (IHC 2+ ≥ 20%), in the 1.8 mg/kg dose cohort, the recommended phase 2 dose (RP2D), the ORR was 46.7% (14/30) with confirmed ORR of 40% (12/30), the DCR was 86.7% (26/30), and the mOS had not yet been reached after a median follow‑up of 14.03 months. Among patients with low/ultra-low CLDN18.2 expression treated at the efficacious dose range of 1.8-2.4 mg/kg, the ORR was 28.6% (6/21) and the DCR was 52.4% (11/21). In addition, multiple patients achieved complete responses (CR). In terms of safety, compared with the data cutoff of December 25, 2025, the incidence of Grade ≥3 treatment‑related adverse events (TRAEs) in the 1.8 mg/kg dose cohort increased slightly from 19.4% to 21.0%, with only 9.7% of patients experiencing dose reduction due to TRAEs. Despite more than six additional months of treatment exposure and follow‑up, the incidence of Grade ≥3 TRAEs remained broadly stable in the 1.8 mg/kg dose cohort. Together with its robust antitumor activity, encouraging survival outcomes and favorable tolerability, these data position ATG-022 as a potential best-in-disease therapy for gastric cancer or gastroesophageal junction adenocarcinoma.

"The dosing of the first patient in CLINCH-3 marks an important step in the clinical evaluation of ATG-022." said Professor Lin Shen of Peking University Cancer Hospital, principal investigator of the CLINCH-3 study. "Patients with advanced gastric or gastroesophageal junction adenocarcinoma continue to face substantial unmet medical needs, particularly after disease progression on existing therapies. The antitumor efficacies and manageable safety profile observed in the Phase I/II study demonstrate therapeutic potential, supporting advancement of ATG-022 into the pivotal Phase III clinical study. CLINCH-3 will provide important evidence regarding whether ATG-022 can improve clinical outcomes for patients with CLDN18.2+ disease. We look forward to conducting this study with scientific rigor and working closely with participating investigators and study centers."

Antengene will continue to advance the three complementary clinical development pathways planned for ATG‑022: CLINCH-3 provides a near-term registration pathway for ATG-022 monotherapy at the optimized RP2D 1.8 mg/kg dose in 3L+ gastric/GEJ cancer with CLDN18.2 IHC 2+ ≥ 20%, establishing ATG-022 in gastric cancer. CLINCH-2 is evaluating ATG-022 in 1L in combination with standard-of-care chemotherapy and anti-PD-1 therapy, targeting the broadest CLDN18.2-positive population starting from IHC 1+ ≥ 1%, with the goal of supporting 1L registration and unlocking the full potential of ATG-022 in gastric cancer. Meanwhile, the CLINCH basket trial is expanding ATG-022 beyond gastric cancer, with encouraging efficacy already observed in multiple non-gastric CLDN18.2-positive solid tumors. Through this strategy, the company aims to maximize the clinical potential of ATG-022 and bring innovative, impactful therapies to patients in China and around the world.

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform.

AnTenGager®, is Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 35 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

PR / IR Contacts: 

Peter Qian

E-mail: [email protected]  

BD Contacts:

Ariel Guo

E-mail: [email protected] 

SOURCE Antengene Corporation Limited

Share this article

CEOs, Heads of State and Government and United Nations leaders identify investment, infrastructure and policy priorities needed to accelerate the global energy transition

NEW YORK, Sept. 20, 2026 /PRNewswire/ -- Business, Government and UN leaders today called for stronger public-private cooperation to accelerate investment in clean energy, strengthen energy security and expand access to affordable power, as the 2026 United Nations Private Sector Forum concluded at UN Headquarters in New York.

Hosted by the UN Global Compact on behalf of UN Secretary-General António Guterres, the invitation-only Forum brought together more than 100 Chief Executive Officers, Heads of State and Government, United Nations leaders and other senior decision-makers for a focused discussion on what is needed to deliver a clean, just and secure energy transition at greater speed and scale.

Participants underscored that growing private-sector demand for clean power and rapidly falling technology costs are creating significant investment opportunities. But they also highlighted persistent barriers to deployment, including insufficient grid infrastructure, policy and regulatory uncertainty, financing constraints and limited energy access in many emerging and developing markets.

The discussions focused on how Governments and business can work together to overcome these barriers and create the conditions for greater private investment in clean energy generation, transmission and supporting infrastructure.

Opening the Forum, Guterres addressed the urgency of accelerating the global energy transition and closing the gap between existing commitments and the pace of change required to keep the 1.5°C goal within reach.

"The companies in this room have the capital, technology, supply chains, consumer base and expertise to supercharge the renewables revolution: By investing in clean power and energy efficiency; Using your purchasing power to create markets for clean technologies; And continuing to build the infrastructure of the future," said UN Secretary-General António Guterres.

Sanda Ojiambo, CEO and Executive Director of the United Nations Global Compact, said: "Business has an essential role to play in delivering the energy transition, and companies are increasingly ready to invest. But ambition and capital alone are not enough. We need the grids, policy frameworks, financing structures and partnerships that allow investment to move from the balance sheet into the real economy. The opportunity is to bring Governments and business together around a common objective: build the clean, affordable and resilient energy systems that companies and communities increasingly need. That is good climate policy, good energy policy and good economic policy."

The Forum took place as geopolitical uncertainty and disruption to global supply chains have increased the strategic importance of secure and diversified energy systems. Participants discussed how accelerating clean energy deployment can support not only climate goals, but also economic resilience, competitiveness and energy security.

A central theme was the need to translate growing demand for clean energy into investment at scale.

Chief Executives and public-sector leaders examined practical approaches to financing clean energy projects, including how blended finance, public investment and risk-sharing mechanisms can help mobilize private capital, particularly in markets where perceived or actual investment risks remain high.

Participants also highlighted grid infrastructure as a critical constraint on the next phase of the energy transition. Rapid growth in renewable generation, electrification and new sources of electricity demand requires investment not only in clean generation, but in the transmission, distribution and storage infrastructure needed to connect new capacity to businesses and consumers.

Discussions also focused on the importance of consistent and predictable policy signals. Participants emphasized that Governments can help unlock greater private investment by creating stable regulatory frameworks, accelerating permitting and infrastructure development, and providing greater long-term visibility for businesses making major capital allocation decisions.

At the same time, leaders stressed that the energy transition must expand opportunity rather than deepen existing inequalities.

In many emerging and developing economies, access to affordable and reliable energy remains a fundamental constraint on economic growth. Participants explored how public and private capital can work together to expand energy access in underserved markets while supporting local economic development, job creation and more resilient energy systems.

The discussions formed part of a collective business response to the UN Secretary-General's call for accelerated action on the clean energy transition, bringing private-sector perspectives directly into dialogue with Governments and the United Nations.

About the United Nations Global Compact

As a special initiative of the United Nations Secretary-General, the UN Global Compact is a call to companies worldwide to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. Our vision is clear: to mobilize business to transform sustainability ambition into action at the scale the world demands. With more than 25,000 participants and a presence in over 100 countries through 5 Regional Hubs and more than 70 Country Networks and expansion territories, the UN Global Compact is the world's largest corporate sustainability initiative.

For more information, follow @globalcompact on social media and visit the UN Global Compact website.

SOURCE United Nations Global Compact

Share this article

01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity

SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- 01F Group through its growth-stage fintech private equity arm, 01Fintech, today announced its investment in DANA, Indonesia's leading digital financial platform. The investment reflects 01F Group's commitment to supporting resilient, locally rooted technology infrastructure that advances financial inclusion and supports Indonesia's real economy. It also strengthens the Group's presence in Asia's fintech sector and reflects its conviction that Indonesia remains one of the region's most dynamic digital-payments markets, underpinned by high digital adoption, a large consumer base and growing demand for technology-enabled financial services.

As Southeast Asia's largest digital economy evolves, digital payments have become an essential part of everyday commerce for consumers and small businesses. Indonesia's digital economy continues to expand rapidly, with digital payments projected to approach USD1 trillion by 2030.

DANA is a leading Indonesian digital e-wallet and digital financial services platform that serves consumers, merchants and financial institutions through a single, integrated ecosystem. Its scale and reach underscore the strength of its platform, including metropolitan and non-metropolitan regions and supports millions of users and micro, small, and medium enterprises (MSMEs), especially across Tier 2 to Tier 4 regions.

01F Group invests in category-defining platforms distinguished by sustainable unit economics, strong local execution, and meaningful utility for the communities they serve. Through this partnership, 01F Group leverages 01Fintech's sector expertise and regional network to support DANA's continued growth and the expansion of its financial-services offering.

Kenny Man, Founder and Managing Partner of 01F Group, stated:

"Our investment in DANA is grounded in three core convictions: the platform's exceptional operational discipline, its essential role in empowering local MSMEs, and the team's unwavering resilience. We are not just capital providers; we look forward to being a long-term partner to DANA as it continues to strengthen Indonesia's digital financial infrastructure and broaden access to trusted financial services."

Vince Iswara, Chief Executive Officer and Co-founder of DANA, said:

"We are pleased to welcome 01Fintech to DANA's journey. Beyond capital, 01Fintech brings specialized fintech expertise, strategic regional connectivity, and a shared commitment to sustainable growth. Together, we remain focused on strengthening our core platform, supporting everyday merchants, and providing trusted financial tools to communities across Indonesia."

Unlocking Ecosystem Value & Strategic Synergy

The investment strengthens 01F Group's footprint in the regional fintech value chain. 01Fintech and DANA will explore opportunities to create value across the broader ecosystem, including:

- Expand Credit & Capital Access: Connect MSMEs on the DANA platform with scalable lending and working capital solutions.

- Broaden access to financial services: Supporting access to products such as micro-insurance, digital savings and wealth-building tools for underserved users.

- Support regional connectivity: Leveraging 01F Group's network to explore more efficient cross-border payment solutions for Indonesian merchants and consumers

01F Group and DANA share a commitment to using technology to support the real economy and create durable value for Indonesian businesses and consumers.

About 01F Group

01F Group is a global investment platform that backs visionary founders and CEOs building next generation technology leaders. The Group combines specialised capital with deep operational partnership to help companies bridge innovation and execution, making digital ecosystems more accessible and scalable. Through a family of focused funds, 01F Group supports companies at different stages of their growth journey: 01Fintech, a growth-stage, Asia-focused private equity strategy that empowers fintech entrepreneurs to innovate and scale, with a particular emphasis on digital financial inclusion; 01F GPS (Global Partner Solutions) scales proven technologies into global market leaders through execution-focused partnerships and joint ventures; and the 01F Intelligence Fund, an investment platform focused on trusted AI systems for the global economy.

Together, 01Fintech, 01F GPS and the 01F Intelligence Fund reflect the Group's long-term approach to technology value creation: backing category‑defining companies, commercialising proven technologies globally and participating in the next wave of growth across fintech, AI and the wider digital economy.

For more information, please visit www.01fgroup.com.

About DANA

DANA (PT DANA Digital Group) is Indonesia's leading digital financial platform, playing a pivotal role in advancing financial inclusion and accelerating the country's digital economy through secure, trusted, and innovative financial services. Since 2018, DANA's integrated ecosystem, including digital payments, QRIS, money transfers, and AI-powered financial solutions, empowers millions of users, businesses, and financial institutions. DANA continues to advance AI innovation, cybersecurity, and fraud prevention, delivering secure financial experiences while helping improve the financial wellbeing of Indonesians.

SOURCE 01F Group

Share this article